PA-BOOMI
11.6.2024 18:01:29 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced that the six inaugural Boomi AI Agents recently unveiled at the company’s Boomi World event will be available in the Boomi Enterprise Platform as part of existing customer licenses, enabling customers to fully harness AI-powered capabilities for unparalleled innovation. These agents include:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611275117/en/
Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation (Graphic: Business Wire)
- Boomi Answers: Save time spent searching through user community discussions and articles. Simply ask questions about Boomi and get the most useful answer from over 240K community users.
- Boomi DataDetective: Stay on top of data privacy, protect sensitive information with AI-powered data classification, and track where data is being moved.
- Boomi DesignGen: Ask GenAI to design integration processes based on 200M+ common patterns and best practices.
- Boomi GPT: Describe integration and automation needs using natural language and have conversations with the Boomi Enterprise Platform to get more meaningful results, faster.
- Boomi Pathfinder: Provide patented suggestions on the next best steps to take when building integration processes.
- Boomi Scribe: Skip manually writing documentation about existing and AI-generated integration processes, and let GenAI handle the busywork of detailing process descriptions and business use cases.
To accelerate innovation, Boomi recently introduced the Boomi AI Agent Framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.
“AI agents are revolutionizing industries by automating repetitive tasks, analyzing vast datasets, and offering personalized customer service,” said Steve Lucas, CEO at Boomi. “Data is the lifeblood of AI, especially with pre-trained transformers and LLM's. Boomi delivers that data, and the Boomi AI Agents improve efficiency, accuracy, and scalability for organizations by operating around the clock with high precision, enhancing decision-making, supporting human workers, and driving innovation. These capabilities lead to increased productivity and cost savings, making them invaluable assets for organizations to maintain a competitive edge."
AI agents are sophisticated software entities designed with a specific scope and personality, enabling them to function within predefined parameters and exhibit particular behaviors. Operating autonomously, they can make decisions using advanced AI-based reasoning algorithms, and can independently take actions to achieve their objectives. AI agents can function with or without human intervention. Additionally, AI agents can either work independently or collaborate with other AI agents, depending on the requirements of the task at hand. This flexibility and autonomy make AI agents highly versatile and capable of performing a wide range of functions across various applications, improving decision-making processes with data-driven insights, and powering innovation by enabling new applications and services.
The Boomi AI Agent Framework includes three types of agents running on the Boomi Enterprise Platform:
Boomi AI Agents
Boomi AI Agents provide AI-powered capabilities within the platform. These capabilities can be utilized through the Boomi GPT conversational user interface (CUI), via specialized GUI, in the process canvas, or via API.
Partner AI Agents
Partner AI agents are pluggable components that allow Boomi Enterprise Platform users to install and use best-of-breed AI functions from Boomi’s network of partners. These agents can be utilized in the same way as Boomi AI Agents, and allow rich capabilities to be incorporated from across the digital ecosystem. An example is the recently announced Boomi FinTalk powered by Vianai agent that allows business users to get detailed responses on financial information via Boomi GPT.
User-created AI Agents
User-created AI agents are developed using the Boomi Enterprise Platform, which provides all the necessary building blocks. Boomi’s connectivity and orchestration capabilities enable users to interact with selected models via API, access proprietary data sources, and automate actions through various applications. The Boomi platform’s process canvas allows the creation of sophisticated workflows to retrieve, combine, filter, and contextualize data, facilitating model prompting and techniques like RAG and fine-tuning. Boomi DataHub serves as an access point and repository for the agents’ knowledge base, while Boomi Flow and Boomi API Management offer human or machine interfaces to package these components into standalone AI agents.
Boomi AI Agents will be available with the July 2024 release of the Boomi Enterprise Platform. More information can be found here.
Additional Resources
- Read up on the latest blog posts from the Boomi leadership team
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611275117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
